Peringatan Keamanan

Most common adverse reactions (? 20% of patients) included: fatigue, decreased appetite, nausea, urinary tract infection, pyrexia, and constipation.

Overdose data for atezolizumab is scarceA181241 but the most common adverse reactions are fatigue, nausea, cough, dyspnea, decreased appetite, alopecia, constipation, diarrhea, peripheral neuropathies, anemia, headache, neutropenia, and vomiting.L7489

Atezolizumab

DB11595

biotech approved investigational

Deskripsi

Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.A18493,L7489 This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy.L7489 Atezolizumab was granted FDA approval on 18 October 2016.L7489 In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.L44246

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half life of atezolizumab is 27 days.[A18492,A181223]
Volume Distribusi The volume of distribution of atezolizumab is 6.91L.[A18492,A181223]
Klirens (Clearance) The clearance of atezolizumab is 0.200L/day.[A18492,A181223]

Absorpsi

Pharmacokinetic analysis was performed in patients with metastatic urothelial carcinoma.A181223 In these patients, the AUC was 2.19-2.73day\*µg/mL/mg, the Cmax was 0.27-0.35µg/mL/mg, and the Cmin was 0.004-0.008µg/mL/mg.A181223

Metabolisme

Monoclonal antibodies are broken down into smaller polypeptides and amino acids.A31470

Rute Eliminasi

Atezolizumab is not renally excreted.A181238

Interaksi Obat

411 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Atezolizumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Atezolizumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Atezolizumab.
Estrone Estrone may increase the thrombogenic activities of Atezolizumab.
Estradiol Estradiol may increase the thrombogenic activities of Atezolizumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Atezolizumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Atezolizumab.
Mestranol Mestranol may increase the thrombogenic activities of Atezolizumab.
Estriol Estriol may increase the thrombogenic activities of Atezolizumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Atezolizumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Atezolizumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Atezolizumab.
Tibolone Tibolone may increase the thrombogenic activities of Atezolizumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Atezolizumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Atezolizumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Atezolizumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Atezolizumab.
Zeranol Zeranol may increase the thrombogenic activities of Atezolizumab.
Equol Equol may increase the thrombogenic activities of Atezolizumab.
Promestriene Promestriene may increase the thrombogenic activities of Atezolizumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Atezolizumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Atezolizumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Atezolizumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Atezolizumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Atezolizumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Atezolizumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Atezolizumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Atezolizumab.
Formononetin Formononetin may increase the thrombogenic activities of Atezolizumab.
Estetrol Estetrol may increase the thrombogenic activities of Atezolizumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Atezolizumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Atezolizumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Atezolizumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Atezolizumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Atezolizumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Atezolizumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Atezolizumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Atezolizumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Atezolizumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Atezolizumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Atezolizumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Atezolizumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Atezolizumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Atezolizumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Atezolizumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Atezolizumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Atezolizumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Atezolizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Atezolizumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Atezolizumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Atezolizumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Atezolizumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Atezolizumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Atezolizumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Atezolizumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Atezolizumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Atezolizumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Atezolizumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Atezolizumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Atezolizumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Atezolizumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Atezolizumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Atezolizumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Atezolizumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Atezolizumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Atezolizumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Atezolizumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Atezolizumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Atezolizumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Atezolizumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Atezolizumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Atezolizumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Atezolizumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Atezolizumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Atezolizumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Atezolizumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Atezolizumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Atezolizumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Atezolizumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Atezolizumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Atezolizumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Atezolizumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Atezolizumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Atezolizumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Atezolizumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Atezolizumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Atezolizumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Atezolizumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Atezolizumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Atezolizumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Atezolizumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Atezolizumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Atezolizumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Atezolizumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Atezolizumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Atezolizumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Atezolizumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Atezolizumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Atezolizumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Atezolizumab.

Target Protein

Programmed cell death 1 ligand 1 CD274
Programmed cell death protein 1 PDCD1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 27412122
    Markham A: Atezolizumab: First Global Approval. Drugs. 2016 Aug;76(12):1227-32. doi: 10.1007/s40265-016-0618-8.
  • PMID: 26952546
    Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4.
  • PMID: 27981577
    Stroh M, Winter H, Marchand M, Claret L, Eppler S, Ruppel J, Abidoye O, Teng SL, Lin WT, Dayog S, Bruno R, Jin J, Girish S: Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma. Clin Pharmacol Ther. 2017 Aug;102(2):305-312. doi: 10.1002/cpt.587. Epub 2017 Jun 9.
  • PMID: 16478695
    Tabrizi MA, Tseng CM, Roskos LK: Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006 Jan;11(1-2):81-8. doi: 10.1016/S1359-6446(05)03638-X.
  • PMID: -
    Mann, Janelle: Atezolizumab (Tecentriq®) Oncology Times. 2017 Feb 25;39(4):31.
  • PMID: 30927173
    Raschi E, Mazzarella A, Antonazzo IC, Bendinelli N, Forcesi E, Tuccori M, Moretti U, Poluzzi E, De Ponti F: Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. Target Oncol. 2019 Apr;14(2):205-221. doi: 10.1007/s11523-019-00632-w.

Contoh Produk & Brand

Produk: 9 • International brands: 0
Produk
  • Tecentriq
    Injection, solution • 1200 mg/20mL • Intravenous • US • Approved
  • Tecentriq
    Injection, solution • 840 mg/14mL • Intravenous • US • Approved
  • Tecentriq
    Solution • 1200 mg / 20 mL • Intravenous • Canada • Approved
  • Tecentriq
    Solution • 840 mg / 14 mL • Intravenous • Canada • Approved
  • Tecentriq
    Injection, solution, concentrate • 1200 mg • Intravenous • EU • Approved
  • Tecentriq
    Injection, solution, concentrate • 840 mg • Intravenous • EU • Approved
  • Tecentriq
    Injection, solution • 1875 mg • Subcutaneous • EU • Approved
  • Tecentriq Hybreza
    Injection • - • Subcutaneous • US • Approved
Menampilkan 8 dari 9 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul